Scripps Research

San Diego, California
Ernest and Jean Hahn Professor at the Skaggs Institute for Chemical Biology


Click here to read about Dr. Schimmel’s latest published work supported by NFCR

One of the most fundamental questions facing scientists today is how seemingly normal cells become cancerous. To better understand how this happens, Dr. Paul Schimmel has dedicated more than 40 years to examining the minute forms and intricate functions of molecular biology.

Dr. Schimmel, a world-renowned biophysical chemist and pioneer in translational medicine, developed the concept of expressed sequence tags in 1983, an approach employed for the Human Genome Project. During his career-long study of essential enzymes, he worked on an enzyme-directed genetic code, known as aminoacyl-tRNA synthetase (aaRS). Humans express 20 different aaRS enzymes, each playing a pivotal role in gene expression. With NFCR funding since 1994, Dr. Schimmel has advanced our understanding of the important role these essential enzymes play in defining the genetic code. Strong associations of some of these enzymes to human diseases has been revealed as well. These associations are now believed to be related to new functions of these proteins studied by Schimmel and collaborator, NFCR-supported scientist, Dr. Xiang-Lei Yang. It now appears that, with these proteins, treatable diseases include chronic and acute inflammation, neuropathy, and cancer progression and metastasis.

One aaRS, SerRS, possesses both anti-tumor and anti-metastasis properties. The scientists showed that SerRS inhibits a pro-cancer gene that triggers release of VEGF, a blood vessel formation factor. Without their own blood supply, tumors are deprived of oxygen and nutrients required for growth. In addition, they discovered that SerRS regulates many immune system-related molecules, implicating a role of SerRS in cancer metastasis.

This research is being conducted in triple negative breast cancer models and tissue samples from patients. They have discovered the expression of SerRS positively correlates with greater survival in breast cancer patients. The results also demonstrate SerRS is significantly downregulated during metastasis, suggest that SerRS is a suppressor of breast cancer and its metastasis. Similar findings of SerRS expression has been found in tissue samples of brain, esophageal, kidney (clear cell), rectal, stomach, and thyroid cancers.  Their significant research may lead to novel therapeutic applications for these cancers.

Dr. Schimmel’s team discovered that one type of tRNA – TyrRS – plays an important role in platelet production and maintenance. Platelets are the tiny blood vessels responsible for forming blood clots; they are often damaged during chemotherapy and cause dangerous bleeding disorders. Dr. Schimmel’s team is developing a TyrRS-based treatment that corrects this damaging side effect.


Paul Schimmel, Ph.D., is a biophysical chemist and he received his B.A. in biochemistry and biophysics from Ohio Wesleyan University in 1962, and then went on to earn his Ph.D. from Massachusetts Institute of Technology (MIT). Currently, Dr. Schimmel is the Ernest and Jean Hahn Professor of Molecular Biology and Chemistry at The Skaggs Institute for Chemical Biology at Scripps Research. He formerly was the John D. and Catherine T. MacArthur Professor of Biochemistry and Biophysics in the Department of Biology at MIT.  He is now MacArthur professor emeritus.

Throughout his career, Dr. Schimmel has received numerous honors and awards, including: the American Chemical Society’s Pfizer Award in Enzyme Chemistry, the Biophysical Society’s Emily M. Gray Award for Significant Contributions to Education in Biophysics, the Chinese Biopharmaceutical Association Brilliant Achievement Award, the Stein and Moore Award of the Protein Society, the American Chemical Society Kathryn C. Hach Award for Entrepreneurial Success, and the ARCS Foundation Scientist of the Year. He is an elected member of the American Academy of Arts and Sciences, the National Academy of Sciences, the American Philosophical Society, the National Academy of Medicine, and the National Academy of Inventors. He has also been active in many scientific and academic organizations and committees, including serving as Chairman of the Division of Biological Chemistry of the American Chemical Society. In addition to these honors and positions, Ohio Wesleyan University (his undergraduate alma mater) conferred on him an honorary Doctor of Science Degree.

Dr. Schimmel has given many honorary lectures, including the Peter Debye Lectures (Cornell University), the Sherman Beychok Lecture (Columbia University), the Reilly Lectures (University of Notre Dame), the Mildred Cohn Lecture (University of Pennsylvania School of Medicine), the University Lecture Series (University of Texas Health Sciences Center (Dallas), the Stanley Gill Memorial Lecture (University of Colorado), the Sir Hans Krebs Lecture (Sheffield, UK), the Nucleic Acids Award Lecture (Biochemical Society and Royal Society of Chemistry, UK), Henry Kamin Lecture (Duke University), the Perlman Lecture Award (American Chemical Society) and the Marker Lecture Series (Pennsylvania State University).

Dr. Schimmel is the author or co-author of more than 500 scientific papers and a widely used three-volume textbook on biophysical chemistry, and he served on the editorial board for numerous scientific journals.

Related Content

Better Understanding of Enzyme Mutation Process Provides Hope for New Pathways to Treatment

Why do protein enzymes cluster together? Few people have bothered to ask this question. Still, a dedicated group of researchers recently embarked on a journey to find the answer. What they found could change many facets of health and healthcare.  The research team, including NFCR-funded senior author Dr. Paul Schimmel, undertook a series of intricate experiments and identified that the location of the clusters appears to play a key role in determining the ‘jobs’ enzymes take on when they’re ejected from the group.  Dr. Schimmel compared the clusters to a bucket of tennis balls, explaining that one tennis ball may eventually be removed to be used as a dog toy while another may be used as a floor protector. Learning that the location of the individual enzymes predicts the job it will take on at a later date has significant implications for the medical world because some of these enzymes can cause disease when mutated. Understanding the patterns and processes may offer new paths for treatment across various medical conditions.  Prior to this study, medical professionals believed enzymes clustered together in order to be more efficient in their protein-making activities. Dr. Schimmel and his team disproved this using CRISPR gene-editing technology. CRISPR has taken the research world by storm, being one of the easiest, most accessible, and quickest gene-editing tools on the market. Using this technology, the team removed enzymes from the cluster and learned that – whether the enzymes were grouped together or separated on their own – they were just as efficient at protein synthesis. This finding prompted the team to question and explore why the enzymes were clustered together if not to improve efficiency. The team believes that the grouping of enzymes helps ensure that mutant enzymes don’t get loose, where they could wreak havoc on other bodily processes. The complex also allows the controlled release of individual enzymes for other functions that are beneficial to health.  This discovery has quickly become viewed as a universal piece of biology, likely starting a domino effect of life-saving discoveries. This game-changing discovery is inspiring; however, it is not Dr. Schimmel’s first significant breakthrough. Dr. Schimmel has long been a worldwide expert in aminoacyl-tRNA synthetases (aaRS). aaRS is a family of enzymes that catalyze the synthesis of proteins from tRNA. Before this study, Dr. Schimmel has advanced our understanding of enzymes’ important role in defining the genetic code. These associations are now believed to be related to new functions of these proteins studied by Schimmel and collaborator, NFCR-supported scientist, Dr. Xiang-Lei Yang. It appears that, with these proteins, treatable diseases include chronic and acute inflammation, neuropathy, and cancer progression and metastasis. Additional Reads You May Enjoy:  NFCR Fellow’s Research Sheds Light on Mechanism for Blood Vessel Formation in Cancer Controlling the Uncontrollable: HER2 Breast Cancer New Research Paves the Way for Cancer-Targeting Viruses and the Identification of Metastatic Cells Stay connected with the cancer community! Receive NFCR’s monthly e-newsletter and blogs featuring stories of inspiration, support resources, cancer prevention tips, and more. Sign up here.

An Unexpected Opportunity: Erin’s Story

NFCR Fellow’s Research Sheds Light on Mechanism for Blood Vessel Formation in Cancer

Almost all living things need oxygen to survive. In human cells, the key to staying healthy is the right balance of oxygen. NFCR fellow Xiang-Lei Yang a professor at Scripps Research Institute has spent much of her career exploring the processes by which tumors sprout new blood vessels when they are oxygen-starved, a process known as angiogenesis. Dr. Xiang-Lei Yang, and NFCR-funded scientist Dr. Paul Schimmel, are worldwide experts in aminoacyl-tRNA synthetases (aaRS). aaRS is a family of enzymes that catalyze the synthesis of proteins from tRNA. While aaRS’s are best known for their role in protein synthesis, Dr. Yang discovered that a particular aaRS, SerRS, also plays a role in inhibiting angiogenesis. Prior angiogenesis research suggests that two genes — c-Myc and HIF-1 — are responsible for promoting blood vessel growth in healthy cells and tumors alike. As such, the turning on and transcription of these genes can promote tumor oxygenation and growth. In particular, c-Myc is one of the most important cancer-causing genes upregulated in many types of cancer. It also controls the gene for the production of VEGF, a blood vessel growth factor. In addition to its role in protein synthesis, SerRS limits blood vessel growth by inhibiting the function of the c-Myc and HIF-1. In the study published in PLOS Biology (December 2020), Yang and her fellow researchers share the discovery that during hypoxia, or oxygen starvation, proteins known as ATM/ATR are activated. The ATM/ATR protein activation “silences” or inhibits SerRS and promotes the formation of new blood vessels. Additionally, in separate studies of mice and human breast tissue, the researchers were able to display that ATM/ATR activation had a blocking effect on SerRS and resulted in reduced tumor size. In researching the role of ATM/ATR activation, and SerRS in breast cancer, Dr. Yang’s team found that the expression of SerRS is positively correlated with a greater rate of survival in breast cancer patients. Also, SerRS is significantly downregulated when metastasis, or cancer spread, occurs. Similar findings have been made in several other cancer types including brain, esophageal, kidney (clear cell), rectal, stomach, and thyroid cancers. These findings suggest that SerRS can inhibit the growth and metastasis of certain cancers and that ATM/ATR activation can counter that inhibition. These discoveries, funded in part by the National Foundation for Cancer Research, are core to our understanding of why and how tumors form new blood vessels and metastasize. As such, these discoveries may lead to novel therapeutic approaches that seek to limit ATM/ATR activation.